LivaNova PLC Q4 2025 Earnings Call Summary

Core Insights - The company experienced its third consecutive year of double-digit organic revenue growth in 2025, primarily driven by the rollout of the Essence heart-lung machine (HLM) and market share gains in cardiopulmonary consumables [1] - The cardiopulmonary segment's growth is supported by a global upgrade cycle, with Essence accounting for 55% of HLM units in 2025 and expected to reach 80% of new placements by 2026 [1] - The growth in epilepsy treatment is attributed to strong commercial execution and the CORE VNS study, which is repositioning VNS Therapy earlier in the treatment algorithm for drug-resistant epilepsy [1] Strategic Shifts - The company is undergoing a significant strategic shift from focusing on legacy core businesses to targeting high-margin, high-growth markets such as obstructive sleep apnea (OSA) [1] - Operational capacity for oxygenators is being expanded to meet demand that currently exceeds market supply, supported by internal manufacturing and third-party component partnerships [1] - A 'Connected Care' digital strategy is being implemented, utilizing a single shared cloud platform across all business segments to streamline physician workflows and enhance patient insights [1]